文献速递消化道肿瘤放疗

不可切除食管癌同步整合推量技术联合选择性淋巴结照射与同步化疗的I/II期放疗剂量递增试验

A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer.
PubMed 文献 · Radiat Oncol · 2019-03-15

该I/II期试验评估不可切除食管癌患者采用同步整合推量(SIB)技术联合选择性淋巴结照射(ENI)与双药化疗的安全性与耐受性。I期确定最大耐受剂量(MTD)为95% PGTV/PTV 59.92/50.40Gy/28f;II期44例采用MTD治疗,70.0%完成至少5周化疗,常见3/4级毒性为白细胞减少(21%)和食管炎(15%)。中位随访16.9个月,1年总生存率、无病生存率和局部无失败生存率分别为76.9%、63.6%和78.8%。

要点

  • I期6例中2例在剂量水平1出现剂量限制性毒性,递增暂停并降级至59.92Gy/2.14Gy/28f。
  • 该降级剂量水平3例均完成至少5周化疗且未达剂量限制性毒性,确定为最大耐受剂量。
  • II期44例采用最大耐受剂量治疗,3/4级毒性以白细胞减少(21%)和食管炎(15%)最常见。

核心结论

  • 同步整合推量技术在最大耐受剂量(95% PGTV/PTV 59.92/50.40Gy/28f)联合选择性淋巴结照射与双药化疗治疗不可切除食管癌是可行且安全的。

研究设计与样本

  • I/II期放疗剂量递增试验,2014年12月至2017年4月共入组53例不可切除食管癌患者。
  • I期预防性PTV固定剂量50.40Gy/1.80Gy/28f,推量区从60.76Gy/2.17Gy/28f开始约每2Gy递增。
  • 选择性淋巴结照射纳入临床靶区,同步给予紫杉醇与奈达铂至少5周。
  • II期患者采用I期获得的最大耐受剂量治疗,评估依从率、生存结果与毒性。

主要发现

  • I期剂量水平1的6例中2例出现剂量限制性毒性。
  • 降级至59.92Gy/2.14Gy/28f后3例均完成至少5周化疗且未达剂量限制性毒性,确定为最大耐受剂量。
  • II期44例中31例(70.0%)完成至少5周化疗。
  • II期最常见的3或4级毒性为白细胞减少(21%)和食管炎(15%)。
  • 中位随访16.9个月,1年总生存率、无病生存率和局部无失败生存率分别为76.9%、63.6%和78.8%。

关键数值与推荐

  • 最大耐受剂量为95% PGTV/PTV 59.92/50.40Gy/28f。
  • 预防性PTV剂量为50.40Gy/1.80Gy/28f。
  • 同步化疗为紫杉醇与奈达铂至少5周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the safety and tolerability of simultaneous integrated boost (SIB) technique concurrent with elective nodal irradiation (ENI) and dual-drug chemotherapy for patients with unresectable esophageal cancer. METHODS: In phase I, the prophylactic PTV received a stable dose of 50.40Gy/1.80Gy/28f while the boost area was planned with 3 consecutive dose levels: the first dose level was 60.76Gy/2.17Gy/28f, and then escalated approximately every 2 Gy. ENI was incorporated in Clinical Target Volume (CTV), and paclitaxel and nedaplatin were given concurrently for at least 5 weeks. In phase II, enrolled patients were treated with Maximum Tolerated Dose (MTD) obtained in phase I and the compliance rate, survival results and toxicities were evaluated. RESULTS: From December 2014 to April 2017, 53 patients were enrolled. In phase I, 2 out of 6 patients developed Dose-Limiting Toxicity (DLT) at dose level 1. Due to excessive treatment-related toxicities, the escalation process was suspended and de-escalated to 59.92Gy /2.14Gy /28 f. Three patients were treated at this dose level, all of whom completed at least 5 weeks of chemotherapy and none of whom reached a DLT, determining the newly added dose level to be the MTD. In phase II, 44 patients were treated with MTD, 31 of them (70.0%) completed at least 5 weeks of chemotherapy. The most common Grade 3 or 4 toxicities in phase II included leukopenia (21%) and esophagitis (15%). With a median follow-up time of 16.9 months, 1-y OS, DFS and local failure-free survival were 76.9, 63.6 and 78.8% respectively. CONCLUSION: The SIB technique was feasible and safe at the MTD (95% PGTV/PTV 59.92/50.40Gy/28f) concurrent with ENI and dual-drug chemotherapy for patients with unresectable esophageal cancer. TRIAL REGISTRATION: clinicaltrials.gov NCT02429622 . Retrospectively registered on April 24, 2015.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li C, Ni W, Wang X, et al. A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer. Radiat Oncol. 2019. PMID: 30876442. doi:10.1186/s13014-019-1249-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。